Insider Transactions in Q1 2025 at Theravance Biopharma, Inc. (TBPH)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 28
2025
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,178
+0.12%
|
$19,602
$9.35 P/Share
|
|
Feb 28
2025
|
Aziz Sawaf SVP & CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+16.7%
|
-
|
|
Feb 28
2025
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+16.7%
|
-
|
|
Feb 28
2025
|
Brett A. Grimaud SVP, GEN COUNSEL AND SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+16.0%
|
-
|
|
Feb 28
2025
|
Aine Miller SVP, DEV & HEAD OF IRE OFFICE |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+25.93%
|
-
|
|
Feb 20
2025
|
Aziz Sawaf SVP & CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
13,751
-4.39%
|
$123,759
$9.66 P/Share
|
|
Feb 20
2025
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
35,129
-1.94%
|
$316,161
$9.66 P/Share
|
|
Feb 20
2025
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Payment of exercise price or tax liability
|
Direct |
15,810
-5.02%
|
$142,290
$9.66 P/Share
|
|
Feb 20
2025
|
Brett A. Grimaud SVP, GEN COUNSEL AND SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
14,534
-4.36%
|
$130,806
$9.66 P/Share
|
|
Feb 20
2025
|
Aine Miller SVP, DEV & HEAD OF IRE OFFICE |
SELL
Payment of exercise price or tax liability
|
Direct |
11,295
-7.5%
|
$101,655
$9.66 P/Share
|
|
Feb 10
2025
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
BUY
Grant, award, or other acquisition
|
Direct |
5,283
+1.65%
|
-
|
|
Jan 21
2025
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Open market or private sale
|
Direct |
4,000
-1.28%
|
$36,000
$9.0 P/Share
|